Intervention Review

You have free access to this content

Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer

  1. Theresa A Lawrie1,*,
  2. Roy Rabbie2,
  3. Clemens Thoma3,
  4. Jo Morrison4

Editorial Group: Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group

Published Online: 21 OCT 2013

Assessed as up-to-date: 14 AUG 2013

DOI: 10.1002/14651858.CD010482.pub2

How to Cite

Lawrie TA, Rabbie R, Thoma C, Morrison J. Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD010482. DOI: 10.1002/14651858.CD010482.pub2.

Author Information

  1. 1

    Royal United Hospital, Cochrane Gynaecological Cancer Group, Bath, UK

  2. 2

    Epsom and St Helier University Hospitals NHS Trust, Department of Respiratory Medicine, London, UK

  3. 3

    University of Oxford, Nuffield Department of Obstetrics & Gynaecology, Oxford, UK

  4. 4

    Musgrove Park Hospital, Department of Obstetrics and Gynaecology, Taunton, Somerset, UK

*Theresa A Lawrie, Cochrane Gynaecological Cancer Group, Royal United Hospital, Education Centre, Bath, BA1 3NG, UK.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 21 OCT 2013


Cited in:


This article has been cited by:

  1. 1
    Günter Emons, Grigor Gorchev, Jalid Sehouli, Pauline Wimberger, Anne Stähle, Lars Hanker, Felix Hilpert, Herbert Sindermann, Carsten Gründker, Philipp Harter, Efficacy and safety of AEZS-108 (INN: Zoptarelin Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: A multicenter Phase II trial of the ago-study group (AGO GYN 5), Gynecologic Oncology, 2014, 133, 3, 427


  2. 2
    Marta Llauradó, Blanca Majem, Tatiana Altadill, Lucia Lanau, Josep Castellví, Jose Luis Sánchez-Iglesias, Silvia Cabrera, Javier De la Torre, Berta Díaz-Feijoo, Asuncion Pérez-Benavente, Eva Colás, Mireia Olivan, Andreas Doll, Francesc Alameda, Xavier Matias-Guiu, Gema Moreno-Bueno, Mark S Carey, Josep Maria Del Campo, Antonio Gil-Moreno, Jaume Reventós, Marina Rigau, MicroRNAs as prognostic markers in ovarian cancer, Molecular and Cellular Endocrinology, 2014, 390, 1-2, 73